Chronic kidney disease (CKD) is a global health problem and is strongly associated with hypertension (HTN) and impaired quality of life. Managing HTN with agents that block the renin angiotensin aldosterone system (RAAS) remains the gold standard, however there is a misleading impression that patients with impaired renal function or those receiving hemodialysis should not be treated with RAAS inhibitors. To date, only a few data in this field are available, given that this population subset is systematically excluded from many major clinical trials. The purpose of this review was to solve the difficult equation regarding the optimal use of RAAS blockade in patients with CKD.

慢性肾病 (CKD) 是一个全球性的健康问题，与高血压 (HTN) 和生活质量受损密切相关。使用阻断肾素血管紧张素醛固酮系统 (RAAS) 的药物治疗 HTN 仍然是金标准，但存在一种误导性的印象，即肾功能受损或接受血液透析的患者不应使用 RAAS 抑制剂治疗。迄今为止，该领域只有少数数据可用，因为该人群子集已被系统地排除在许多主要临床试验之外。本综述的目的是解决关于 CKD 患者最佳使用 RAAS 阻滞剂的难题。